Publications | Page 337 | Pathology & Laboratory Medicine

Filter By Faculty

Filter by Principal Investigator

2009

Peng H-, Halsey K, Sun C-, Manucha V, Nugent S, Rodgers WH, et al. Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma. Cancer. 2009;117(6):463-72.

Diaz-Meco MT, Abu-Baker S. The Par-4/PTEN connection in tumor suppression. Cell Cycle. 2009;8(16):2518-22.

Reszko AE, Magro CM, Diktaban T, Sadick NS. Histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis using an ex vivo model. J Drugs Dermatol. 2009;8(4):377-82.

Chiu A, Frizzera G, Mathew S, Hyjek EM, Chadburn A, Tam W, et al. Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. Mod Pathol. 2009;22(11):1507-17.

Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009;71(2):130-9.

Martinez JL, Fajardo A, Garmendia L, Hernandez A, Linares JF, Martínez-Solano L, et al. A global view of antibiotic resistance. FEMS Microbiol Rev. 2009;33(1):44-65.

Liu L, Lee S, Zhang J, Peters SB, Hannah J, Zhang Y, et al. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell. 2009;34(4):451-60.

Seshan SV, J Jennette C. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med. 2009;133(2):233-48.

Nassar A, Cohen C, Siddiqui MT. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009;37(9):629-35.

Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, et al. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009;36(4):290-301.